PE20060165A1 - COMPOUNDS WITH SULFONE GROUP AS GAMMA SECRETASE INHIBITORS - Google Patents

COMPOUNDS WITH SULFONE GROUP AS GAMMA SECRETASE INHIBITORS

Info

Publication number
PE20060165A1
PE20060165A1 PE2005000380A PE2005000380A PE20060165A1 PE 20060165 A1 PE20060165 A1 PE 20060165A1 PE 2005000380 A PE2005000380 A PE 2005000380A PE 2005000380 A PE2005000380 A PE 2005000380A PE 20060165 A1 PE20060165 A1 PE 20060165A1
Authority
PE
Peru
Prior art keywords
compounds
sulfone group
gamma secretase
alkylen
rent
Prior art date
Application number
PE2005000380A
Other languages
Spanish (es)
Inventor
Theodros Asberom
John W Clader
Hubert B Josien
Zhiqiang Zhao
Mark Mcbriar
Dmitri A Pissarnitski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20060165A1 publication Critical patent/PE20060165A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS QUE CONTIENEN UN GRUPO SULFONA DE FORMULA (I), EN DONDE R1 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO POR UNO O MAS R5; R2 ES -(C0-C12)ALQUILEN-C(O)-Y, -(C0-C6)ALQUILEN-(C3-C6)CICLOALQUILEN-(C0-C6)ALQUILEN-C(O)-Y, -(C0-C12)ALQUILEN-S(O2)-Y, -(C0-C6)ALQUILEN-(C3-C6)CICLOALQUILEN-(C0-C6)ALQUILEN-S(O2)-Y, ENTRE OTROS, DONDE EL ALQUILEN O CICLOALQUILEN ESTAN OPCIONALMENTE SUSTITUIDO POR HIDROXI; Y ES a), b), c), d), ENTRE OTROS; CADA R3 DE (R3)2 SE SELECCIONA DE H, OH, ALQUILO O ACILO(C1-C6); LA PARTE (R3)2 JUNTO AL C ANULAR DEFINE UN CARBONILO, SOLO SI CUANDO m ES MAYOR QUE 1, A LO SUMO UN CARBONILO ESTA PRESENTE; CADA R3A Y R3B ES INDEPENDIENTEMENTE H O ALQUILO(C1-C6); R5 ES HALO, OH, CF3 Y -0-(C1-C6). TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA SECRETASA GAMMA Y SON UTILES EN EL TRATAMIENTO DEL MAL DE ALZHEIMERREFERS TO COMPOUNDS THAT CONTAIN A SULFONE GROUP OF FORMULA (I), WHERE R1 IS ARYL OR HETEROARYL, OPTIONALLY SUBSTITUTED BY ONE OR MORE R5; R2 ES - (C0-C12) ALKYLEN-C (O) -Y, - (C0-C6) ALKYLEN- (C3-C6) CYCLOALKYLENE- (C0-C6) ALKYLEN-C (O) -Y, - (C0- C12) RENT-S (O2) -Y, - (C0-C6) RENT- (C3-C6) CYCLOALKYLEN- (C0-C6) RENT-S (O2) -Y, AMONG OTHERS, WHERE THE RENTAL OR CYCLE RENTAL ARE OPTIONALLY REPLACED BY HYDROXY; AND IS a), b), c), d), AMONG OTHERS; EACH R3 OF (R3) 2 IS SELECTED FROM H, OH, ALKYL OR ACILO (C1-C6); PART (R3) 2 NEXT TO THE C ANNULAR DEFINES A CARBONYL, ONLY IF WHEN m IS GREATER THAN 1, AT THE MOST ONE CARBONYL IS PRESENT; EACH R3A AND R3B IS INDEPENDENTLY H OR ALKYL (C1-C6); R5 IS HALO, OH, CF3 AND -0- (C1-C6). IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE INHIBITORS OF THE GAMMA SECRETASE AND ARE USEFUL IN THE TREATMENT OF ALZHEIMER'S EVIL

PE2005000380A 2004-04-05 2005-04-05 COMPOUNDS WITH SULFONE GROUP AS GAMMA SECRETASE INHIBITORS PE20060165A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55952904P 2004-04-05 2004-04-05

Publications (1)

Publication Number Publication Date
PE20060165A1 true PE20060165A1 (en) 2006-04-13

Family

ID=34965070

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000380A PE20060165A1 (en) 2004-04-05 2005-04-05 COMPOUNDS WITH SULFONE GROUP AS GAMMA SECRETASE INHIBITORS

Country Status (13)

Country Link
US (1) US20060004004A1 (en)
EP (1) EP1740570A2 (en)
JP (1) JP2007531742A (en)
KR (1) KR20070010144A (en)
CN (1) CN1950358A (en)
AR (1) AR049377A1 (en)
AU (1) AU2005230681B2 (en)
CA (1) CA2563033A1 (en)
IL (1) IL178392A0 (en)
PE (1) PE20060165A1 (en)
TW (1) TWI300410B (en)
WO (1) WO2005097768A2 (en)
ZA (1) ZA200608274B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1789404B1 (en) * 2004-06-30 2010-03-24 Schering Corporation Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
US8133857B2 (en) * 2006-03-07 2012-03-13 The Brigham and Women's FHospital, Inc. NOTCH inhibition in the treatment of atherosclerosis
WO2007141029A1 (en) * 2006-06-08 2007-12-13 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Specific protease inhibitors and their use in cancer therapy
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2010004309A (en) * 2007-10-19 2010-05-03 Janssen Pharmaceutica Nv Piperidinyl and piperazinyl modulators of î³-secretase.
PL2475428T3 (en) 2009-09-11 2015-12-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2545047T3 (en) 2010-03-10 2014-07-28 Probiodrug Ag Heterocyclic Inhibitors of Glutaminyl Cyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US9629891B2 (en) 2011-10-17 2017-04-25 Nationwide Children's Hospital, Inc. Products and methods for aortic abdominal aneurysm
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2020016377A1 (en) 2018-07-19 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
EP4244391A1 (en) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
JP2005504042A (en) * 2001-08-03 2005-02-10 シェーリング　コーポレイション Sulfonamide derivatives such as gamma secretase inhibitors
US6683091B2 (en) * 2001-08-03 2004-01-27 Schering Corporation Gamma Secretase inhibitors
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
US20040171614A1 (en) * 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
US7256186B2 (en) * 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
CA2637897A1 (en) * 2006-01-20 2007-07-26 Schering Corporation Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors

Also Published As

Publication number Publication date
AU2005230681B2 (en) 2009-07-30
US20060004004A1 (en) 2006-01-05
AU2005230681A1 (en) 2005-10-20
EP1740570A2 (en) 2007-01-10
ZA200608274B (en) 2008-08-27
WO2005097768A2 (en) 2005-10-20
KR20070010144A (en) 2007-01-22
CA2563033A1 (en) 2005-10-20
AR049377A1 (en) 2006-07-26
IL178392A0 (en) 2007-02-11
CN1950358A (en) 2007-04-18
JP2007531742A (en) 2007-11-08
WO2005097768A3 (en) 2005-12-15
TWI300410B (en) 2008-09-01
TW200602050A (en) 2006-01-16

Similar Documents

Publication Publication Date Title
PE20060165A1 (en) COMPOUNDS WITH SULFONE GROUP AS GAMMA SECRETASE INHIBITORS
PE20061106A1 (en) DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE
PE20071245A1 (en) INDOL SULFONAMIDE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMs)
CA2620129C (en) Diaminopyrimidines as p2x3 and p2x2/3 modulators
NO20055688L (en) Organic compounds
HK1112910A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
PE20071090A1 (en) 5-PIRAZOLPIPERIDINES- (SUBSTITUTED)
GEP20146046B (en) Organic compounds
PE20071321A1 (en) BENCENSULFONIL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS
MX2010006046A (en) Gamma secretase modulators.
DE602004007808D1 (en) NEW GAMMA SECRETASE INHIBITORS
DK1730147T3 (en) Substituted 1,4,8-triazaspiro [4.5] decan-2-one compounds for the treatment of obesity
WO2009020140A1 (en) Adamantylurea derivative
UY29197A1 (en) N-SULPHONYLAMINOBENCIL-2-PHENOXYACETAMIDE SUBSTITUTED COMPOUNDS
JO3116B1 (en) Pyrazoloquinoline derivative as pde9 inhibitors
BRPI0519292A2 (en) organic compounds
PE20091349A1 (en) COMPOUNDS DERIVED FROM SPIRO 1,3,4-TIADIAZOL AS INHIBITORS OF KSP KINESINE ACTIVITY
UY27503A1 (en) NEW DERIVATIVES OF PIPERAZINA
ES2328496T3 (en) 1,4,8-TRIAZA-ESPIRO (4,5) DECAN-2-ONA SUBSTITUTED COMPOUNDS.
ATE486071T1 (en) AZABICYCLOÄ3.1.0ÜHEXANE DERIVATIVES AS MODULATORS OF THE DOPAMINE D3 RECEPTOR
LT2005107A (en) A method for the preparation of enantiomerically pure mirtazapine
PE20090548A1 (en) AZA-BICYCLOHEXANE COMPOUNDS AS THROMBIN INHIBITORS
CL2020002157A1 (en) Triazine derivatives for the treatment of neurotrophin-related diseases.
BRPI0409376A (en) indene derivatives as pharmaceutical agents
MXPA05013823A (en) Organic compounds.

Legal Events

Date Code Title Description
FC Refusal